Presented by Jean-Yves Blay (Leon Berard Center, Lyon, France)
This downloadable slide collection, based on a webinar presented by World Sarcoma Network Chairman Professor Jean-Yves Blay, highlights and summarizes key recent findings in sarcoma presented at the 2018 ASCO Annual Meeting and the 2018 ESMO Congress.
This educational initiative was funded by Eli Lilly and Company.
On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.
Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).
Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.
The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.
Supplementing androgen deprivation therapy with enzalutamide delays radiologic progression in men with metastatic castration-sensitive prostate cancer, indicate phase III trial findings presented at the 2019 ASCO Genitourinary Cancers Symposium.
Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.
Addition of the androgen receptor antagonist darolutamide to androgen deprivation therapy improves metastasis-free survival in patients with castration-resistant prostate cancer, indicate ARAMIS trial results.
Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.
This program was made possible thanks to an independent educational grant from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
